Low-Cost Antiseptic Gel To Save Newborns From Umbilical Cord Infections Wins Approval

by Shirley Johanna on  May 2, 2016 at 2:35 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

GlaxoSmithKline has won approval from the regulators for its antiseptic gel developed from a mouthwash to save millions of newborns in the developing countries.
Low-Cost Antiseptic Gel To Save Newborns From Umbilical Cord Infections Wins Approval
Low-Cost Antiseptic Gel To Save Newborns From Umbilical Cord Infections Wins Approval

The British pharmaceutical company reformulated its Corsodyl mouthwash into an antiseptic gel. The gel aids in preventing umbilical cord infections in newborn babies.

GSK developed the antiseptic gel called Umbipro with a charity group called Save the Children. The wonder gel is targeted to developing countries and the UN estimates 422,000 lives can be saved over five years.

Umbilical cord infections are more prevalent in Africa and Asia, where there are more births at home typically done using unsterile objects, such as dung ash, for the umbilical cord stump.

The gel will be mainly sold at a not-for-profit price. It is designed to hold up both hot and humid conditions without needing much refrigeration as both continents endure such weather condition.

Dr. Pauline Williams, a senior GSK scientist at GSK's UK research and development center in Stevenage initiated the efforts in coming up with the gel which took four years to develop.

In a report by the United Nations in 2012, chlorhexidine was identified as a forgotten "life-saving commodity".

The report stated that chlorhexidine had the potential to save baby lives if made available across poor parts of Africa and Asia.

Dr Williams realized that Chlorhexidine was being used in GSK's mouthwash brand Corsodyl.

"It's been a great example of bringing together expertise and resources from across the company to work on something that can make a big difference to public health," said Dr Williams.

Umbipro received approval from the European Medicines Agency on April 29. This breakthrough is one of the first approvals for any medical drug to reach the developing countries.

However, the antiseptic gel is yet to be approved by the local regulators in all the countries where the company intends to serve its drug. GSK is confident though that it could pass these local approvals.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Exomphalos 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive